4.3 -0.4 (-8.51%) | 04-25 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 7.31 | 1-year : | 8.86 |
Resists | First : | 6.26 | Second : | 7.59 |
Pivot price | 5.25 | |||
Supports | First : | 4.11 | Second : | 3.41 |
MAs | MA(5) : | 4.61 | MA(20) : | 5.52 |
MA(100) : | 7.4 | MA(250) : | 10.01 | |
MACD | MACD : | -0.7 | Signal : | -0.7 |
%K %D | K(14,3) : | 15.8 | D(3) : | 17 |
RSI | RSI(14): 25.3 | |||
52-week | High : | 17.2 | Low : | 4.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRME ] has closed above bottom band by 10.8%. Bollinger Bands are 6.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.6 - 4.63 | 4.63 - 4.66 |
Low: | 4.06 - 4.08 | 4.08 - 4.11 |
Close: | 4.26 - 4.3 | 4.3 - 4.34 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Prime Medicine (NYSE:PRME) Reaches New 12-Month Low at $4.32 - MarketBeat
Tue, 23 Apr 2024
Prime Medicine (NYSE:PRME) Stock Price Up 8.8% - MarketBeat
Tue, 23 Apr 2024
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming ... - Yahoo Finance
Tue, 27 Feb 2024
Great week for Prime Medicine, Inc. (NASDAQ:PRME) institutional investors after losing 47% over the previous year - Simply Wall St
Sun, 25 Feb 2024
With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors - Yahoo Finance
Tue, 20 Feb 2024
Prime Medicine completes $161 million public offering By Investing.com - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 120 (M) |
Shares Float | 57 (M) |
Held by Insiders | 25 (%) |
Held by Institutions | 56 (%) |
Shares Short | 9,920 (K) |
Shares Short P.Month | 9,220 (K) |
EPS | -2.19 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.44 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -43.2 % |
Return on Equity (ttm) | -88.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.56 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -165 (M) |
Levered Free Cash Flow | -96 (M) |
PE Ratio | -1.98 |
PEG Ratio | 0 |
Price to Book value | 2.98 |
Price to Sales | 0 |
Price to Cash Flow | -3.12 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |